aTyr Pharma stock crashes on Phase III pulmonary sarcoidosis fail
aTyr Pharma shares plunged more than 80% after its Phase III trial in pulmonary sarcoidosis failed to meet its primary…
Immunology
-
-
Novartis returns to Monte Rosa for second time in a year with $5.7bn deal
Novartis has ventured back to Monte Rosa Therapeutics tasked with finding more immune-mediated disease drug candidates, signing a licensing deal…
-
AbbVie extends Rinvoq exclusivity by four years after generics settlements
AbbVie has bolstered the sales outlook of its blockbuster autoimmune drug Rinvoq (upadacitinib) by extending its exclusivity until 2037. The…
-
Oxford University and Ellison Institute link for AI vaccine research
The University of Oxford has announced the launch of a new vaccine research programme in collaboration with the Ellison Institute…
-
Moderna’s updated Covid-19 vaccine gets Canadian approval
Moderna has secured approval from Health Canada for Spikevax, its updated Covid-19 mRNA vaccine, which targets the SARS-CoV-2 LP.8.1 variant.…
-
Sanofi receives orphan status from EMA for rilzabrutinib
Sanofi has received orphan designation from the European Medicines Agency (EMA) for rilzabrutinib, a reversible covalent Bruton’s tyrosine kinase (BTK)…
-
US eosinophilic oesophagitis market to reach $1.19bn by 2030
The eosinophilic oesophagitis (EoE) market in the US is forecast to grow from $202 million in 2020 to $1.19 billion…
-
BMS and Bain Capital forge $300m immunology spinoff
Following the pharmaceutical giant’s intentions to home in on its immunology portfolio, Bristol Myers Squibb (BMS) has teamed up with…
-
HS market forecast to reach $7.8bn across 7MM by 2034
The hidradenitis suppurativa (HS) market across the seven major pharmaceutical markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)…
-
Hengrui Pharma and GSK link across key therapeutic areas
Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several therapeutic…
